Navigation Links
Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
Date:9/13/2011

ASHBURN, Va., Sept. 13, 2011 /PRNewswire/ -- Innocoll, Inc. announced top-line results from its phase 2 clinical trial investigating XaraColl for the management of post-operative pain and also announced it has received a "Notice of Allowability" for its XaraColl patent application in the United States.

The clinical trial was a U.S. multi-centered, double-blind, 2-way study comparing the analgesic effect of XaraColl versus placebo in patients undergoing herniorrhaphy via open laparotomy. Patients receiving XaraColl demonstrated a statistically significant reduction in the total use of opioid medication through 24 and 48 hours post-surgery as well as a statistically significant increase in the time before patients took any opioid medication.

The "Notice of Allowability" received from the United States Patent and Trademark Office for U.S. patent application #20080241245 covers products comprising any amino amide or amino ester anesthetic in a collagen matrix intended for the provision of local analgesia or anesthesia.

Dr. Michael Myers, Innocoll's President and CEO commented, "We are pleased to announce two such important milestones for XaraColl and for the company.  XaraColl is an important commercial asset for Innocoll and these latest developments serve as a positive endorsement of its progress to date."

About XaraColl:

XaraColl is a biodegradable and fully resorbable collagen/bupivacaine matrix formulated and manufactured using Innocoll's proprietary collagen-based drug delivery technology, CollaRx. This technology achieves a high concentration of drug at the target tissue, while maintaining low systemic levels.  XaraColl is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery.  The product is available in several different strengths, and is designed such that multiple units can be used per patient, for optimum dosing flexibility and efficacy.  XaraColl is easy to use and can be cut or rolled depending on the surgical setting and can be used laparoscopically.  

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm®, DermaSil™ and Liquicoll®.  Approved products based on the Company's technologies include:  Collatamp G®,  Septocoll®, Collieva®, CollaCare®, Collexa®, Zorpreva™ and, LidoColl®

Other products in development include:  CollaRx surgical Implant in phase 3 (licensed in the U.S. to Baxter Healthcare, a division of Baxter International Inc.) Cogenzia® in phase 3 development for the adjuvant treatment of infected Diabetic Foot Ulcers, and CollaGUARD®, for the prevention of surgical adhesions, which has been submitted for approval in the EU. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
2. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Country Club in Miami Beach to host its Swirl: Miami Wine Tasting Event ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association ... Annual Meeting. KLS is a longtime supporter of the event. , "We are ... Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid ... sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental Group ... for a dinner for two at the Cheesecake Factory. , Tickets are available ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
Breaking Medicine News(10 mins):